Authors: Hidalgo, M Aylesworth, C Hammond, LA Britten, CD Weiss, G Stephenson, J Schwartz, G Patnaik, A Smith, L Molpus, K Felton, S Gupta, E Ferrante, KJ Tortora, A Sonnichsen, DS Skillings, J Rowinsky, EK

Citation: M. Hidalgo et al., Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel, J CL ONCOL, 19(9), 2001, pp. 2493-2503

Authors: Tolcher, AW Eckhardt, SG Kuhn, J Hammond, L Weiss, G Rizzo, J Aylesworth, C Hidalgo, M Patnaik, A Schwartz, G Felton, S Campbell, E Rowinsky, EK

Citation: Aw. Tolcher et al., Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties, J CL ONCOL, 19(11), 2001, pp. 2937-2947

Authors: Tolcher, AW Aylesworth, C Rizzo, J Izbicka, E Campbell, E Kuhn, J Weiss, G Von Hoff, DD Rowinsky, EK

Citation: Aw. Tolcher et al., A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenousinfusion in patients with advanced solid tumors, ANN ONCOL, 11(3), 2000, pp. 333-338

Authors: Rowinsky, EK Humphrey, R Hammond, LA Aylesworth, C Smetzer, L Hidalgo, M Morrow, M Smith, L Garner, A Sorensen, JM Von Hoff, DD Eckhardt, SG

Citation: Ek. Rowinsky et al., Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patientswith solid malignancies, J CL ONCOL, 18(1), 2000, pp. 178-186

Authors: Petit, T Aylesworth, C Burris, H Ravdin, P Rodriguez, G Smith, L Peacock, N Smetzer, L Bellet, R Von Hoff, DD Rowinsky, EK

Citation: T. Petit et al., A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies, ANN ONCOL, 10(2), 1999, pp. 223-229